Mutual of America Capital Management’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $6.43M | Sell |
|
|||||
|
2025
Q2 | $6.19M | Sell |
|
|||||
|
2025
Q1 | $5.68M | Sell |
|
|||||
|
2024
Q4 | $7.3M | Sell |
|
|||||
|
2024
Q3 | $6.29M | Sell |
|
|||||
|
2024
Q2 | $7.93M | Sell |
|
|||||
|
2024
Q1 | $8.18M | Sell |
|
|||||
|
2023
Q4 | $8M | Sell |
|
|||||
|
2023
Q3 | $7.14M | Sell |
|
|||||
|
2023
Q2 | $6.67M | Sell |
|
|||||
|
2023
Q1 | $7.86M | Sell |
|
|||||
|
2022
Q4 | $9.43M | Buy |
|
|||||
|
2022
Q3 | $8.16M | Sell |
|
|||||
|
2022
Q2 | $7.79M | Sell |
|
|||||
|
2022
Q1 | $8.11M | Buy |
|
|||||
|
2021
Q4 | $7.22M | Buy |
|
|||||
|
2021
Q3 | $8M | Buy |
|
|||||
|
2021
Q2 | $8.1M | Sell |
|
|||||
|
2021
Q1 | $8.21M | Buy |
|
|||||
|
2020
Q4 | – | Sell |
|
|||||
|
2020
Q3 | $115K | Hold |
|
|||||
|
2020
Q2 | $146K | Sell |
|
|||||
|
2020
Q1 | $1.45M | Sell |
|
|||||
|
2019
Q4 | $2.75M | Sell |
|
|||||
|
2019
Q3 | $2.34M | Sell |
|
|||||
|
2019
Q2 | $2.2M | Sell |
|
|||||
|
2019
Q1 | $2.98M | Sell |
|
|||||
|
2018
Q4 | $3.42M | Sell |
|
|||||
|
2018
Q3 | $8.24M | Sell |
|
|||||
|
2018
Q2 | $10.5M | Sell |
|
|||||
|
2018
Q1 | $8.92M | Sell |
|
|||||
|
2017
Q4 | $8.35M | Sell |
|
|||||
|
2017
Q3 | $6.92M | Buy |
|
|||||
|
2017
Q2 | $5.14M | Buy |
|
|||||
|
2017
Q1 | $3.08M | Sell |
|
|||||
|
2016
Q4 | $2.81M | Buy |
|
|||||
|
2016
Q3 | $3.64M | Hold |
|
|||||
|
2016
Q2 | $3.27M | Buy |
|
|||||
|
2016
Q1 | $2.84M | Sell |
|
|||||
|
2015
Q4 | $4.07M | Buy |
|
|||||
|
2015
Q3 | $2.85M | Buy |
|
|||||
|
2015
Q2 | $2.42M | Buy |
|
|||||
|
2015
Q1 | $1.97M | Buy |
|